A single droplet digital PCR for ESR1 activating mutations detection in plasma

Emmanuelle Jeannot(Inserm), Lauren Darrigues(Inserm), Marc Michel(Inserm), Marc‐Henri Stern(Inserm), Jean‐Yves Pierga(Inserm), Aurore Rampanou(Inserm), Samia Melaabi(Université Paris Sciences et Lettres), Camille Benoist(Université Paris Sciences et Lettres), Ivan Bièche(Université Paris Sciences et Lettres), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Radouane El Ayachy(Université Paris Sciences et Lettres), Aurélien Noret(Université Paris Sciences et Lettres), Nicolas Epaillard(Université Paris Sciences et Lettres), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), François‐Clément Bidard(Inserm), Charlotte Proudhon(Inserm)
Oncogene
February 10, 2020
10.1038/s41388-020-1174-y
Cited by 64Open Access
Full Text

Abstract

Related Papers

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy, Yang Shen, Helen Won et al.|Nature Genetics|2013|1.3k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson, Yi-Mi Wu, Pankaj Vats et al.|Nature Genetics|2013|1.2k
Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Charlotte Fribbens, Ben O’Leary, Lucy Kilburn et al.|Journal of Clinical Oncology|2016|713
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter et al.|Clinical Cancer Research|2014|659
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li, Dong Shen, Jieya Shao et al.|Cell Reports|2013|622